Local governments continue to spend left-over “fiscal recovery” funds on wish list projects with no accountability from Congress.
The 340B Drug Discount Program Needs an Overhaul
CAGW has long been concerned with the misuse of the 340B Program.
Congress Should not Double Down on Devastating Drug Price Controls
House Democrats’ new bill on price controls will devastate future drug development and raise costs.
Another Government Report Proves That PBMs Save Taxpayers Money
PBMs lower healthcare costs and another government agency overspent because a PBM was not used.
FDA Flavor Bans Create a Dangerous Black Market
The FDA must now attempt to fix the mess it has created by banning flavored tobacco products.
Biden’s Budget and the SMART Prices Act Will Devastate Drug Development
Pharmaceutical price controls in President Biden’s budget and the SMART Choices Act will devastate drug development.
New Study Exposes More Exploitation and Waste in the 340B Drug Discount Program
A new study, “The 340B Drug Discount Program Exceeds $100B in 2022,” shows the program is misused.
Taxpayers Do Not Get Everything They Want But They Get What They Need
The Fiscal Responsibility Act is what taxpayers need and will lead to more of what they want to reduce wasteful spending.
Harm Reduction Is Vital on World Vape Day
Tobacco harm reduction products like e-cigarettes are effective tools that help adults successfully quit smoking.
Recognizing Women’s Medical Innovations on World IP Day
Intellectual property rights must be protected to encourage future research and development of life saving cures.